In last trading session, Pyxis Oncology Inc (NASDAQ:PYXS) saw 0.63 million shares changing hands with its beta currently measuring 1.06. Company’s recent per share price level of $1.28 trading at -$0.08 or -5.88% at ring of the bell on the day assigns it a market valuation of $76.11M. That closing price of PYXS’s stock is at a discount of -435.16% from its 52-week high price of $6.85 and is indicating a premium of 3.91% from its 52-week low price of $1.23.
For Pyxis Oncology Inc (PYXS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Pyxis Oncology Inc (NASDAQ:PYXS) trade information
Upright in the red during last session for losing -5.88%, in the last five days PYXS remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $1.28 price level, adding 8.57% to its value on the day. Pyxis Oncology Inc’s shares saw a change of -17.95% in year-to-date performance and have moved -1.54% in past 5-day. Pyxis Oncology Inc (NASDAQ:PYXS) showed a performance of -17.95% in past 30-days.
Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 87.2% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -446.88% in reaching the projected high whereas dropping to the targeted low would mean a loss of -446.88% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -118.72% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 40.99% while estimates for its earnings growth in next 5 years are of 12.25%.
Pyxis Oncology Inc (NASDAQ:PYXS)’s Major holders
DEEP TRACK CAPITAL, LP is the top institutional holder at PYXS for having 4.18 million shares of worth $13.85 million. And as of 2024-06-30, it was holding 6.9164 of the company’s outstanding shares.
The second largest institutional holder is LAURION CAPITAL MANAGEMENT LP, which was holding about 3.86 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.3826 of outstanding shares, having a total worth of $12.78 million.
On the other hand, iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 1.34 shares of worth $1.71 million or 2.25% of the total outstanding shares. The later fund manager was in possession of 1.29 shares on Sep 30, 2024 , making its stake of worth around $1.66 million in the company or a holder of 2.18% of company’s stock.
